Physicians have long theorized that being able to precisely warm and cool patients, depending on their conditions and settings, would be beneficial in both cardiovascular and neurological procedures, and recent clinical evidence has shown temperature management to be even more important than initially thought.Medivance is looking to develop a non-invasive external temperature management system that is both simple to operate and suitable for a variety of settings for both precise warming and cooling. The company believes an external device avoids the risk of an invasive procedure and can be used easily by neurologists, who generally aren't comfortable inserting catheters.In striving to solve a difficult technology problem (external, non-invasive temperature management) with an easy-to-use device, Medivance is looking to avoid a problem that plagues many device companies--falling in love with complex, hard-to-operate technology. While a very sophisticated device may work effectively, a steep learning curve inhibits broad adoption because physicians are notoriously reluctant to adopt new technology unless it closely resembles current techniques. Medivance's system enables an anesthesiologist to regulate patient temperature without intruding on the surgical field and without heating up the OR, a win-win for surgeons.
by Stephen Levin
In 1997, veteran medical device inventor/entrepreneur Norman R. Weldon, having successfully launched and/or headed several cardiovascular companies including Cordis Corp....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.